GYG1 and infection: In summary, we demonstrate that a versatile peptide GN1, coupled with robust synergistic effect, anti‐virulence properties, and satisfied safety profiles, represents a promising β‐lactams adjuvant to tackle the recalcitrant infection caused by MRSA.